Vol.6 No.4 – 2: Protective effect of omega-3 on Doxorubicin-induced hepatotoxicity in male albino rats

/0 Comments/in , , /by

By: 1Farozia I. Moussa, 1Horeya S. Abd El-Gawad, 1Salwa S. Mahmoud, 2Faiza A. Mahboub, and 1Saliha G.Abdelseyd

1Department of Zoology, Faculty of Science, Alexandria University, Egypt

2Department of Biology, Faculty of Applied Sciences, Umm Al-Qura University, Saudi Arabia

Abstract

Doxorubicin (DOX) is an antineoplastic anthracycline used to treat various forms of cancer. Although DOX is an effective chemotherapeutic agent, it has been documented to cause oxidative damage in several body organs. The present study aimed to investigate the protective effects of omega-3 against doxorubicin-induced hepatic toxicity in adult male rats. Animals were divided into four groups. The first group was orally administered with 0.5ml corn oil and served as a control group. The second group was treated with omega-3 fatty acid (400mg/kg b.w) daily for 30 days. The third group was injected intraperitoneally with a single dose of DOX (30mg/kg b.w). Animals in the fourth group were treated with omega-3 at the same dose level as those of group 2 followed by intraperitoneal injection of a single dose of DOX as in the third group. Injecting animals with DOX induces various histological changes in the liver. These changes include congestion and dilatation of blood vessels, leucocytic infiltration, cytoplasmic vacuolization, degenerated hepatocytes, and pyknotic nuclei. Moreover, DOX caused a significant elevation in serum ALT, AST, LDH, lipid profile, total bilirubin, total protein, albumin, and globulin after 4 weeks of treatment. It also caused an increase in malondialdehyde (MDA) and depletion of the antioxidant enzymes, catalase (CAT), superoxide dismutase (SOD), and reduced glutathione reduced (GSH). Treating animals with omega 3 fatty acids in combination with DOX led to an improvement in the histological and biochemical changes induced by DOX together with a significant decrease in the level of MDA and an increase in the activity of antioxidant enzymes. The results of the present work indicated that omega-3 fatty acid had a protective effect against liver damage induced by Doxorubicin and this is due to its antioxidant activities.

Protective-effect-of-omega-3-on-Doxorubicin-induced-hepatotoxicity-converted

Download PDF

Vol.6 No.4 – 1: Evaluation of the cardioprotective effect of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy

/0 Comments/in , , /by

By: Zeinab Al kasaby  Zalat* 1, Hosny A. Elewa2,Mohamed Abdel-Latif3 , Mohamed A. Alm El-Din4, Neeven A. Kohaf 5

  1. Assoc. Professor and Head of Clinical Pharmacy Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. (Pharm.D., Ph.D.) (zeinabalkasaby.pharmg@azhar.edu.eg)
  2. Assoc. professor and Head of Pharmacy Practice Department, Faculty of Pharmacy, Horus University, Dominate City, Egypt. (Pharm.D, Ph.D.)
  3. Professor and Head of Clinical Pharmacy Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt. (Ph.D.)
  4. Assoc. Professor, Department of Clinical Oncology, Faculty of Medicine, Tanta University, Tanta, Egypt. (MD)
  5. Master degree in pharmaceutical sciences, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. (M.Sc.)

Abstract

Aim: Anthracycline-induced cardiotoxicity is the most common constraint of its use in the treatment of various types of cancer. This study aimed to investigate the benefits of the addition of the l-carnitine / silymarin to anthracycline chemotherapy in patients with breast cancer. Methods: 83 patients were recruited from Clinical Oncology Department, Tanta University, Egypt, then prospectively randomized to receive their anthracycline-containing therapeutic regimen, control group (n=33), or anthracycline plus l-carnitine, l-carnitine group (n=25), or anthracycline plus silymarin, silymarin group (n= 25). Blood samples were collected at the beginning and after 6 months to measure LDH, CK-MB, cTn I, Anticardiolipin IgG, Fe, ferritin, and TIBC and % of saturation. % EF was documented. Data were statistically analyzed by ANOVA and paired t-test. P <0.05 was statistically significant. Results: The addition of l-carnitine to anthracycline chemotherapy has a significantly improved EF% (P=0.003), Anticardiolipin IgG (P=0.001), ferritin (P=0.001), and TIBC (P=0.011). The supplementation with silymarin to anthracycline chemotherapy had a statistically significant decrease in Anticardiolipin IgG (P=0.000), iron (P=0.001), ferritin (P= 0.001), TIBC (P=0.007), and % saturation (P=0.001). Silymarin group showed a significant decrease in iron profile compared to the l-carnitine group. Conclusion: The co-administration of l-carnitine or silymarin with anthracycline chemotherapy represents a new therapeutic strategy for better control of anthracycline-induced cardiotoxicity. Silymarin resulted in more beneficial effects on the iron profile compared to l-carnitine with anthracycline or anthracycline chemotherapy alone.

Evaluation-of-the-cardioprotective-effect-of-l-carnitine-and-silymarin-in-cancer-patients-receiving-anthracycline-containing-chemotherapy-converted

Download PDF